ERBB2 and breast cancer: Median OS (mOS) in patients with luminal A tumors was not-reached and 128.1 months (95% CI 108.0–182.6) for those with luminal B tumors, 101.2 months (95% CI 17.1–not estimable) for patients with basal-like BC, and 274.5 months (95% CI 70.3-–not estimable) for those HER2-enriched BC (p = 0.010).